Login to Your Account



CLOT-SPECIFIC STREPTOKINASE REDUCES THE RISK OF BLEEDING

Innovation in India? Symmetrix launches phase II of targeted thrombolytic

By Alfred Romann
Staff Writer

Wednesday, February 19, 2014

HONG KONG – Regulators in India have approved phase II trials for the protein drug that targets blood clots and could help treat heart attack patients with fewer risks and side effects than existing treatments. It may be the first biopharmaceutical compound fully developed in the country.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription